Literature DB >> 27394694

Dose prescription in carbon ion radiotherapy: How to compare two different RBE-weighted dose calculation systems.

Silvia Molinelli1, Giuseppe Magro2, Andrea Mairani3, Naruhiro Matsufuji4, Nobuyuki Kanematsu4, Taku Inaniwa4, Alfredo Mirandola2, Stefania Russo2, Edoardo Mastella2, Azusa Hasegawa4, Hiroshi Tsuji4, Shigeru Yamada4, Barbara Vischioni2, Viviana Vitolo2, Alfredo Ferrari5, Mario Ciocca2, Tadashi Kamada4, Hirohiko Tsujii4, Roberto Orecchia6, Piero Fossati6.   

Abstract

BACKGROUND AND
PURPOSE: In carbon ion radiotherapy (CIRT), the use of different relative biological effectiveness (RBE) models in the RBE-weighted dose (DRBE) calculation can lead to deviations in the physical dose (Dphy) delivered to the patient. Our aim is to reduce target Dphy deviations by converting prescription dose values.
MATERIAL AND METHODS: Planning data of patients treated at the National Institute of Radiological Sciences (NIRS) were collected, with prescribed doses per fraction ranging from 3.6Gy (RBE) to 4.6Gy (RBE), according to the Japanese semi-empirical model. The Dphy was Monte Carlo (MC) re-calculated simulating the NIRS beamline. The local effect model (LEM)_I was then applied to estimate DRBE. Target median DRBE ratios between MC+LEM_I and NIRS plans determined correction factors for the conversion of prescription doses. Plans were re-optimized in a LEM_I-based commercial system, prescribing the NIRS uncorrected and corrected DRBE.
RESULTS: The MC+LEM_I target median DRBE was respectively 15% and 5% higher than the NIRS reference, for the lowest and highest dose levels. Uncorrected DRBE prescription resulted in significantly lower target Dphy in re-optimized plans, with respect to NIRS plans.
CONCLUSIONS: Prescription dose conversion factors could minimize target physical dose variations due to the use of different radiobiological models in the calculation of CIRT RBE-weighted dose.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Carbon ion radiotherapy; RBE-weighted dose; Radiobiological models

Mesh:

Substances:

Year:  2016        PMID: 27394694     DOI: 10.1016/j.radonc.2016.05.031

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis.

Authors:  Amelia Barcellini; Viviana Vitolo; Lorenzo Cobianchi; Andrea Peloso; Alessandro Vanoli; Alfredo Mirandola; Angelica Facoetti; Maria Rosaria Fiore; Alberto Iannalfi; Barbara Vischioni; Francesco Cuccia; Sara Ronchi; Maria Bonora; Giulia Riva; Rachele Petrucci; Emma D'Ippolito; Francesca Dal Mas; Lorenzo Preda; Francesca Valvo
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Applications of nanodosimetry in particle therapy planning and beyond.

Authors:  Antoni Rucinski; Anna Biernacka; Reinhard Schulte
Journal:  Phys Med Biol       Date:  2021-12-10       Impact factor: 3.609

3.  Proton and carbon ion beam treatment with active raster scanning method in 147 patients with skull base chordoma at the Heidelberg Ion Beam Therapy Center-a single-center experience.

Authors:  Matthias Mattke; Matteo Ohlinger; Nina Bougatf; Semi Harrabi; Robert Wolf; Katharina Seidensaal; Thomas Welzel; Falk Röder; Sabine Gerum; Malte Ellerbrock; Oliver Jäkel; Thomas Haberer; Klaus Herfarth; Matthias Uhl; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2022-09-23       Impact factor: 4.033

4.  Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy.

Authors:  Alberto Iannalfi; Emma D'Ippolito; Giulia Riva; Silvia Molinelli; Sara Gandini; Gisela Viselner; Maria Rosaria Fiore; Barbara Vischioni; Viviana Vitolo; Maria Bonora; Sara Ronchi; Rachele Petrucci; Amelia Barcellini; Alfredo Mirandola; Stefania Russo; Alessandro Vai; Edoardo Mastella; Giuseppe Magro; Davide Maestri; Mario Ciocca; Lorenzo Preda; Francesca Valvo; Roberto Orecchia
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

5.  Physics and biomedical challenges of cancer therapy with accelerated heavy ions.

Authors:  Marco Durante; Jürgen Debus; Jay S Loeffler
Journal:  Nat Rev Phys       Date:  2021-09-17

6.  Rectum Dose Constraints for Carbon Ion Therapy: Relative Biological Effectiveness Model Dependence in Relation to Clinical Outcomes.

Authors:  Kyungdon Choi; Silvia Molinelli; Stefania Russo; Alfredo Mirandola; Maria Rosaria Fiore; Barbara Vischioni; Piero Fossati; Rachele Petrucci; Irene Turturici; Jon Espen Dale; Francesca Valvo; Mario Ciocca; Andrea Mairani
Journal:  Cancers (Basel)       Date:  2019-12-21       Impact factor: 6.639

7.  Radiomics and Dosiomics for Predicting Local Control after Carbon-Ion Radiotherapy in Skull-Base Chordoma.

Authors:  Giulia Buizza; Chiara Paganelli; Emma D'Ippolito; Giulia Fontana; Silvia Molinelli; Lorenzo Preda; Giulia Riva; Alberto Iannalfi; Francesca Valvo; Ester Orlandi; Guido Baroni
Journal:  Cancers (Basel)       Date:  2021-01-18       Impact factor: 6.639

8.  FRoG-A New Calculation Engine for Clinical Investigations with Proton and Carbon Ion Beams at CNAO.

Authors:  KyungDon Choi; Stewart B Mein; Benedikt Kopp; Giuseppe Magro; Silvia Molinelli; Mario Ciocca; Andrea Mairani
Journal:  Cancers (Basel)       Date:  2018-10-23       Impact factor: 6.639

9.  A step towards international prospective trials in carbon ion radiotherapy: investigation of factors influencing dose distribution in the facilities in operation based on a case of skull base chordoma.

Authors:  G Vogin; A Wambersie; M Koto; T Ohno; M Uhl; P Fossati; J Balosso
Journal:  Radiat Oncol       Date:  2019-02-01       Impact factor: 3.481

10.  Carbon Ion Dose Constraints in the Head and Neck and Skull Base: Review of MedAustron Institutional Protocols.

Authors:  Piero Fossati; Ana Perpar; Markus Stock; Petra Georg; Antonio Carlino; Joanna Gora; Giovanna Martino; Eugen B Hug
Journal:  Int J Part Ther       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.